BOSTON– enGene Holdings Inc., a clinical-stage genetic medicines company, announced that Dr. Raj Pruthi has resigned from his role as Chief Medical Officer. His departure will take effect on June 16, 2025.
Dr. Pruthi, who joined enGene to support its clinical advancement efforts, will assist in the transition of his responsibilities over the coming weeks. The company stated that his duties will be redistributed among its team of urology and clinical experts.
“We thank Dr. Pruthi for his dedication and service and wish him continued success in his future endeavors,” the company said in a statement.
enGene is developing non-viral genetic therapies aimed at mucosal tissues and organs, with a focus on addressing diseases with unmet medical needs. Its lead candidate, detalimogene voraplasmid—also known as detalimogene and formerly EG-70—is currently being evaluated in a multi-cohort Phase 2 clinical trial for patients with non-muscle invasive bladder cancer (NMIBC). The trial includes a pivotal cohort for patients with carcinoma in situ unresponsive to Bacillus Calmette-Guérin (BCG) treatment.
The company’s investigational therapies are based on its proprietary DDX (Dually Derivatized Oligochitosan) platform, which enables efficient delivery of genetic material such as DNA and RNA to mucosal surfaces.
